Puma Biotechnology Stock Price, News & Analysis (NASDAQ:PBYI)

$67.05 0.00 (0.00 %)
(As of 02/20/2018 04:00 PM ET)
Previous Close$67.05
Today's Range$66.10 - $68.70
52-Week Range$28.35 - $136.90
Volume476,209 shs
Average Volume1.11 million shs
Market Capitalization$2.57 billion
P/E Ratio-8.19
Dividend YieldN/A
Beta0.18

About Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology logoPuma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

Receive PBYI News and Ratings via Email

Sign-up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:PBYI
CUSIPN/A
Phone+1-424-2486500

Debt

Debt-to-Equity RatioN/A
Current Ratio1.23%
Quick Ratio1.23%

Price-To-Earnings

Trailing P/E Ratio-8.18681318681319
Forward P/E Ratio-8.26
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.70 per share
Price / Book11.76

Profitability

Trailing EPS($8.19)
Net Income$-276,010,000.00
Net MarginsN/A
Return on Equity-208.58%
Return on Assets-145.91%

Miscellaneous

Employees160
Outstanding Shares37,530,000

Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology Inc (NASDAQ:PBYI) released its earnings results on Thursday, November, 9th. The biopharmaceutical company reported ($2.07) EPS for the quarter, topping analysts' consensus estimates of ($2.50) by $0.43. The biopharmaceutical company earned $6.10 million during the quarter, compared to analysts' expectations of $3.78 million. During the same period in the prior year, the company posted ($1.11) earnings per share. View Puma Biotechnology's Earnings History.

When will Puma Biotechnology make its next earnings announcement?

Puma Biotechnology is scheduled to release their next quarterly earnings announcement on Thursday, March, 1st 2018. View Earnings Estimates for Puma Biotechnology.

Where is Puma Biotechnology's stock going? Where will Puma Biotechnology's stock price be in 2018?

9 equities research analysts have issued 12-month price targets for Puma Biotechnology's shares. Their predictions range from $68.00 to $146.00. On average, they expect Puma Biotechnology's share price to reach $110.56 in the next year. View Analyst Ratings for Puma Biotechnology.

Who are some of Puma Biotechnology's key competitors?

Who are Puma Biotechnology's key executives?

Puma Biotechnology's management team includes the folowing people:

  • Alan H. Auerbach, Chairman of the Board, President, Chief Executive Officer (Age 47)
  • Charles R. Eyler, Senior Vice President - Finance and Administration, Treasurer (Age 69)
  • Richard P. Bryce, Chief Scientific Officer, Chief Medical Officer (Age 59)
  • Steven Lo, Chief Commercial Officer (Age 50)
  • Jay M. Moyes, Independent Director (Age 63)
  • Adrian M Senderowicz, Independent Director (Age 53)
  • Troy E. Wilson Ph.D. J.D., Independent Director (Age 48)
  • Frank E. Zavrl, Independent Director (Age 51)

Who owns Puma Biotechnology stock?

Puma Biotechnology's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.36%), Redmile Group LLC (2.43%), Franklin Resources Inc. (2.22%), Wells Fargo & Company MN (1.40%), Emerald Advisers Inc. PA (1.07%) and Rock Springs Capital Management LP (1.00%). Company insiders that own Puma Biotechnology stock include Adage Capital Partners Gp, LL, Alan H Auerbach, Charles R Eyler, Richard Paul Bryce and Robert Charnas. View Institutional Ownership Trends for Puma Biotechnology.

Who sold Puma Biotechnology stock? Who is selling Puma Biotechnology stock?

Puma Biotechnology's stock was sold by a variety of institutional investors in the last quarter, including Ascend Capital LLC, Deutsche Bank AG, Bank of Montreal Can, Tekla Capital Management LLC, Nicholas Investment Partners LP, HBK Investments L P, Candriam Luxembourg S.C.A. and Teachers Advisors LLC. Company insiders that have sold Puma Biotechnology company stock in the last year include Adage Capital Partners Gp, LL, Alan H Auerbach, Charles R Eyler and Richard Paul Bryce. View Insider Buying and Selling for Puma Biotechnology.

Who bought Puma Biotechnology stock? Who is buying Puma Biotechnology stock?

Puma Biotechnology's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Wells Fargo & Company MN, Eagle Asset Management Inc., Carillon Tower Advisers Inc., Rice Hall James & Associates LLC, Eversept Partners LLC, Artal Group S.A. and Two Sigma Advisers LP. View Insider Buying and Selling for Puma Biotechnology.

How do I buy Puma Biotechnology stock?

Shares of Puma Biotechnology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Puma Biotechnology's stock price today?

One share of Puma Biotechnology stock can currently be purchased for approximately $67.05.

How big of a company is Puma Biotechnology?

Puma Biotechnology has a market capitalization of $2.57 billion. The biopharmaceutical company earns $-276,010,000.00 in net income (profit) each year or ($8.19) on an earnings per share basis. Puma Biotechnology employs 160 workers across the globe.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 Wilshire Blvd Ste 2150, LOS ANGELES, CA 90024-4106, United States. The biopharmaceutical company can be reached via phone at +1-424-2486500 or via email at [email protected]


MarketBeat Community Rating for Puma Biotechnology (PBYI)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  330 (Vote Outperform)
Underperform Votes:  264 (Vote Underperform)
Total Votes:  594
MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Puma Biotechnology (NASDAQ:PBYI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.782.892.892.88
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $110.56$130.67$130.67$112.13
Price Target Upside: 21.62% upside31.65% upside26.86% upside55.73% upside

Puma Biotechnology (NASDAQ:PBYI) Consensus Price Target History

Price Target History for Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology (NASDAQ:PBYI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2018Bank of AmericaLower Price TargetBuy -> Buy$135.00 -> $115.00HighView Rating Details
1/24/2018CitigroupLower Price TargetBuy -> Buy$164.00 -> $146.00HighView Rating Details
1/24/2018Credit Suisse GroupLower Price TargetOutperform -> Outperform$147.00 -> $106.00HighView Rating Details
1/24/2018Royal Bank of CanadaLower Price TargetSector Perform$77.00HighView Rating Details
1/24/2018JPMorgan Chase & Co.Lower Price TargetOverweight -> Buy$138.00 -> $91.00HighView Rating Details
1/24/2018CowenDowngradeOutperform -> Market Perform$123.00 -> $68.00HighView Rating Details
11/10/2017BarclaysReiterated RatingBuy$103.00 -> $122.00N/AView Rating Details
10/27/2017Leerink SwannBoost Price TargetPositive -> Outperform$140.00N/AView Rating Details
10/2/2017Stifel NicolausBoost Price TargetBuy$110.00 -> $130.00LowView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Puma Biotechnology (NASDAQ:PBYI) Earnings History and Estimates Chart

Earnings by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology (NASDAQ PBYI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018($1.97)N/AView Earnings Details
11/9/2017Q3 2017($2.50)($2.07)$3.78 million$6.10 millionViewN/AView Earnings Details
8/9/2017Q2 2017($1.32)($2.10)ViewN/AView Earnings Details
5/10/2017Q1 2017($2.06)($1.97)ViewN/AView Earnings Details
3/1/2017Q4($1.92)($2.04)ViewN/AView Earnings Details
11/9/2016Q3 2016($2.00)($2.02)ViewN/AView Earnings Details
8/9/2016Q2 2016($2.20)($2.05)ViewN/AView Earnings Details
5/10/2016Q1($1.99)($1.28)ViewN/AView Earnings Details
2/29/2016Q4($1.95)($1.23)ViewN/AView Earnings Details
11/9/2015Q3($1.84)($1.87)ViewN/AView Earnings Details
8/10/2015Q2($1.55)($1.13)ViewN/AView Earnings Details
5/11/2015Q1($1.25)($1.02)ViewN/AView Earnings Details
3/2/2015($1.15)($1.59)ViewN/AView Earnings Details
11/10/2014($1.27)($1.19)ViewN/AView Earnings Details
8/11/2014Q214($0.66)($1.05)ViewN/AView Earnings Details
5/12/2014($0.48)($0.67)ViewN/AView Earnings Details
3/3/2014Q413($0.49)($0.46)ViewN/AView Earnings Details
11/12/2013Q3 2013($0.46)($0.49)ViewN/AView Earnings Details
8/6/2013Q2 2013($0.44)($0.43)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.40)ViewN/AView Earnings Details
4/1/2013Q413($0.70)($0.25)ViewN/AView Earnings Details
11/14/2012Q312($1.29)ViewN/AView Earnings Details
8/14/2012Q2 2012($0.74)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.59)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Puma Biotechnology (NASDAQ:PBYI) Earnings Estimates

2018 EPS Consensus Estimate: ($5.58)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.87)($1.87)($1.87)
Q2 20181($1.55)($1.55)($1.55)
Q3 20181($1.21)($1.21)($1.21)
Q4 20181($0.95)($0.95)($0.95)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Puma Biotechnology (NASDAQ:PBYI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Puma Biotechnology (NASDAQ PBYI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.10%
Insider Trades by Quarter for Puma Biotechnology (NASDAQ:PBYI)
Institutional Ownership by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology (NASDAQ PBYI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/22/2018Alan H AuerbachInsiderSell10,692$92.75$991,683.004,155,931View SEC Filing  
1/22/2018Richard Paul BryceSVPSell1,860$92.75$172,515.0025,379View SEC Filing  
12/1/2017Charles R EylerInsiderSell1,322$105.46$139,418.12View SEC Filing  
9/29/2017Richard Paul BryceSVPSell15,000$120.00$1,800,000.0042,239View SEC Filing  
9/7/2017Richard Paul BryceSVPSell15,000$100.09$1,501,350.0028,239View SEC Filing  
7/20/2017Alan H AuerbachInsiderSell13,175$94.73$1,248,067.754,170,623View SEC Filing  
7/20/2017Richard Paul BryceSVPSell1,998$94.48$188,771.0427,246View SEC Filing  
7/3/2017Richard Paul BryceSVPSell5,000$87.10$435,500.0034,237View SEC Filing  
6/12/2017Adage Capital Partners Gp, L.LMajor ShareholderSell247,260$80.32$19,859,923.20View SEC Filing  
6/5/2017Adage Capital Partners Gp, L.LMajor ShareholderSell507,128$87.84$44,546,123.52View SEC Filing  
5/26/2017Adage Capital Partners Gp, L.LMajor ShareholderSell1,235,700$75.38$93,147,066.00View SEC Filing  
2/1/2017Robert CharnasInsiderSell3,008$31.83$95,744.6428,461View SEC Filing  
1/20/2017Alan H AuerbachInsiderSell10,202$33.24$339,114.484,179,798View SEC Filing  
1/20/2017Richard Paul BryceSVPSell2,293$33.24$76,219.3229,237View SEC Filing  
7/6/2015Richard Paul BryceSVPSell3,000$110.03$330,090.00View SEC Filing  
11/8/2013Adage Capital Partners Gp Llcmajor shareholderBuy22,549$38.92$877,607.08View SEC Filing  
11/5/2013Adage Capital Partners Gp Llcmajor shareholderBuy280,700$39.60$11,115,720.00View SEC Filing  
10/9/2013Adage Capital Partners Gp Llcmajor shareholderBuy140,900$40.44$5,697,996.00View SEC Filing  
12/18/2012Adage Capital Partners Gp LlcMajor ShareholderBuy29,560$19.00$561,640.00View SEC Filing  
12/12/2012Adage Capital Partners Gp LlcMajor ShareholderBuy30,400$19.00$577,600.00View SEC Filing  
12/11/2012Adage Capital Partners Gp LlcMajor ShareholderBuy140,040$18.98$2,657,959.20View SEC Filing  
10/24/2012Thomas MalleyDirectorBuy10,000$16.00$160,000.00View SEC Filing  
10/18/2012Adage Capital Partners Gp LlcMajor ShareholderBuy610,000$16.00$9,760,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Puma Biotechnology (NASDAQ PBYI) News Headlines

Source:
DateHeadline
Puma Biotechnology (PBYI) to Release Quarterly Earnings on TuesdayPuma Biotechnology (PBYI) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 20 at 4:30 AM
Puma Biotechnology (PBYI) & Incyte (INCY) Financial ReviewPuma Biotechnology (PBYI) & Incyte (INCY) Financial Review
www.americanbankingnews.com - February 18 at 3:23 PM
Puma Biotechnology (PBYI) Upgraded by BidaskClub to BuyPuma Biotechnology (PBYI) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - February 17 at 11:40 AM
Zacks: Analysts Expect Puma Biotechnology Inc (PBYI) to Announce -$1.98 Earnings Per ShareZacks: Analysts Expect Puma Biotechnology Inc (PBYI) to Announce -$1.98 Earnings Per Share
www.americanbankingnews.com - February 17 at 1:16 AM
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial ResultsPuma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results
finance.yahoo.com - February 15 at 4:55 PM
Today’s Research Reports on Trending Tickers: Nektar Therapeutics and Puma BiotechnologyToday’s Research Reports on Trending Tickers: Nektar Therapeutics and Puma Biotechnology
finance.yahoo.com - February 15 at 8:25 AM
Puma Biotechnology to Present at LEERINK Partners Global Healthcare ConferencePuma Biotechnology to Present at LEERINK Partners Global Healthcare Conference
finance.yahoo.com - February 8 at 8:36 AM
Puma Biotechnology Inc (PBYI) Receives Average Recommendation of "Buy" from AnalystsPuma Biotechnology Inc (PBYI) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 6 at 12:36 PM
Puma Biotechnology Inc (PBYI) Expected to Post Quarterly Sales of $19.68 MillionPuma Biotechnology Inc (PBYI) Expected to Post Quarterly Sales of $19.68 Million
www.americanbankingnews.com - February 2 at 2:22 PM
Puma Biotech (PBYI) Enters Exclusive Licensing Agreement to ... - StreetInsider.comPuma Biotech (PBYI) Enters Exclusive Licensing Agreement to ... - StreetInsider.com
www.streetinsider.com - February 2 at 9:30 AM
Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Basket Trial Evaluating Neratinib in ... - Business Wire (press release)Puma Biotechnology Announces Publication of Results from Phase II SUMMIT 'Basket' Trial Evaluating Neratinib in ... - Business Wire (press release)
www.businesswire.com - February 2 at 9:30 AM
Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Greater ChinaPuma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Greater China
finance.yahoo.com - February 2 at 9:30 AM
A Licensing Agreement Won't Protect This Biotech From A TakeoverA Licensing Agreement Won't Protect This Biotech From A Takeover
finance.yahoo.com - February 1 at 4:05 PM
Puma Biotech (PBYI) Reports Publication of Results from Phase II SUMMIT Basket Trial Evaluating Neratinib in HER2 and HER3 MutantPuma Biotech (PBYI) Reports Publication of Results from Phase II SUMMIT 'Basket' Trial Evaluating Neratinib in HER2 and HER3 Mutant
www.streetinsider.com - January 31 at 4:08 PM
Do Options Traders Know Something About Puma Biotechnology (PBYI) Stock We Dont?Do Options Traders Know Something About Puma Biotechnology (PBYI) Stock We Don't?
finance.yahoo.com - January 30 at 10:02 AM
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - January 30 at 10:02 AM
Do Options Traders Know Something About Puma Biotechnology (PBYI) Stock We Don't?Do Options Traders Know Something About Puma Biotechnology (PBYI) Stock We Don't?
finance.yahoo.com - January 30 at 10:02 AM
Puma Biotechnology and Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in IsraelPuma Biotechnology and Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Israel
finance.yahoo.com - January 30 at 10:02 AM
Puma Biotechnology (PBYI) Downgraded to "Market Perform" at CowenPuma Biotechnology (PBYI) Downgraded to "Market Perform" at Cowen
www.americanbankingnews.com - January 28 at 6:06 PM
Puma Biotechnology (PBYI) PT Lowered to $91.00 at JPMorgan Chase & Co.Puma Biotechnology (PBYI) PT Lowered to $91.00 at JPMorgan Chase & Co.
www.americanbankingnews.com - January 28 at 5:10 PM
Puma Biotechnology (PBYI) Price Target Cut to $77.00 by Analysts at Royal Bank of CanadaPuma Biotechnology (PBYI) Price Target Cut to $77.00 by Analysts at Royal Bank of Canada
www.americanbankingnews.com - January 28 at 3:28 PM
Puma Biotechnology Target of Unusually Large Options Trading (PBYI)Puma Biotechnology Target of Unusually Large Options Trading (PBYI)
www.americanbankingnews.com - January 28 at 1:06 AM
Puma Biotechnology (PBYI) Downgraded by BidaskClubPuma Biotechnology (PBYI) Downgraded by BidaskClub
www.americanbankingnews.com - January 27 at 2:18 PM
Zacks Investment Research Upgrades Puma Biotechnology (PBYI) to HoldZacks Investment Research Upgrades Puma Biotechnology (PBYI) to Hold
www.americanbankingnews.com - January 26 at 8:38 PM
FY2018 Earnings Estimate for Puma Biotechnology Inc Issued By Leerink Swann (PBYI)FY2018 Earnings Estimate for Puma Biotechnology Inc Issued By Leerink Swann (PBYI)
www.americanbankingnews.com - January 26 at 11:29 AM
Heres Why Puma Biotechnology Inc. Is Getting Beaten Down TodayHere's Why Puma Biotechnology Inc. Is Getting Beaten Down Today
finance.yahoo.com - January 25 at 4:06 PM
ICYMI: MicroCap Trading Ideas, Puma Biotech, A Valeant Bear CallICYMI: MicroCap Trading Ideas, Puma Biotech, A Valeant Bear Call
finance.yahoo.com - January 25 at 9:28 AM
Bank of America Lowers Puma Biotechnology (PBYI) Price Target to $115.00Bank of America Lowers Puma Biotechnology (PBYI) Price Target to $115.00
www.americanbankingnews.com - January 24 at 7:18 PM
Puma Biotechnology Inc (PBYI) SVP Richard Paul Bryce Sells 1,860 SharesPuma Biotechnology Inc (PBYI) SVP Richard Paul Bryce Sells 1,860 Shares
www.americanbankingnews.com - January 24 at 7:04 PM
Insider Selling: Puma Biotechnology Inc (PBYI) Insider Sells 10,692 Shares of StockInsider Selling: Puma Biotechnology Inc (PBYI) Insider Sells 10,692 Shares of Stock
www.americanbankingnews.com - January 24 at 6:28 PM
EU Unlikely to Approve Pumas Nerlynx in 2018, Stock DownEU Unlikely to Approve Puma's Nerlynx in 2018, Stock Down
finance.yahoo.com - January 24 at 4:23 PM
Puma Biotechnology Inc: A European Approval for Neratinib Seems UnlikelyPuma Biotechnology Inc: A European Approval for Neratinib Seems Unlikely
finance.yahoo.com - January 24 at 4:23 PM
With EU Approval For Puma Biotechs Breast Cancer Drug Unlikely, Cowen DowngradesWith EU Approval For Puma Biotech's Breast Cancer Drug Unlikely, Cowen Downgrades
finance.yahoo.com - January 24 at 4:23 PM
What Happened To Puma Biotechnology?What Happened To Puma Biotechnology?
finance.yahoo.com - January 24 at 4:23 PM
Here's Why Puma Biotechnology Inc. Is Getting Beaten Down TodayHere's Why Puma Biotechnology Inc. Is Getting Beaten Down Today
finance.yahoo.com - January 24 at 4:23 PM
EU Unlikely to Approve Puma's Nerlynx in 2018, Stock DownEU Unlikely to Approve Puma's Nerlynx in 2018, Stock Down
finance.yahoo.com - January 24 at 4:23 PM
Puma Biotechnology (PBYI) Given New $146.00 Price Target at CitigroupPuma Biotechnology (PBYI) Given New $146.00 Price Target at Citigroup
www.americanbankingnews.com - January 24 at 10:28 AM
Puma Biotechnology Inc. (PBYI) Has Plunged To An 8-Month LowPuma Biotechnology Inc. (PBYI) Has Plunged To An 8-Month Low
www.nasdaq.com - January 24 at 10:01 AM
Puma Biotech shares drop more than 20% as European OK of breast cancer drug unlikelyPuma Biotech shares drop more than 20% as European OK of breast cancer drug unlikely
finance.yahoo.com - January 24 at 10:01 AM
Puma Biotechnology Announces Results of CHMP Oral Explanation for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast CancerPuma Biotechnology Announces Results of CHMP Oral Explanation for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
finance.yahoo.com - January 24 at 10:01 AM
Puma Biotech shares plummet after concerning turn in EuropePuma Biotech shares plummet after 'concerning turn' in Europe
finance.yahoo.com - January 24 at 10:01 AM
Here’s What’s Moving Amarin Corporation and Puma BiotechnologyHere’s What’s Moving Amarin Corporation and Puma Biotechnology
finance.yahoo.com - January 24 at 10:01 AM
Puma Biotechnologys (PBYI) Outperform Rating Reaffirmed at Credit Suisse GroupPuma Biotechnology's (PBYI) Outperform Rating Reaffirmed at Credit Suisse Group
www.americanbankingnews.com - January 24 at 9:38 AM
Noteworthy Monday Option Activity: YUM, THC, PBYI - NasdaqNoteworthy Monday Option Activity: YUM, THC, PBYI - Nasdaq
www.nasdaq.com - January 23 at 6:53 AM
Credit Suisse Group Analysts Give Puma Biotechnology (PBYI) a $147.00 Price TargetCredit Suisse Group Analysts Give Puma Biotechnology (PBYI) a $147.00 Price Target
www.americanbankingnews.com - January 22 at 5:10 PM
 Analysts Anticipate Puma Biotechnology Inc (PBYI) Will Post Quarterly Sales of $19.35 Million Analysts Anticipate Puma Biotechnology Inc (PBYI) Will Post Quarterly Sales of $19.35 Million
www.americanbankingnews.com - January 16 at 10:52 PM
Why is Puma (PBYI) Stock Up More than 150% in a Year's Time?Why is Puma (PBYI) Stock Up More than 150% in a Year's Time?
finance.yahoo.com - January 16 at 10:21 AM
Puma Biotechnology (PBYI) Downgraded by Zacks Investment ResearchPuma Biotechnology (PBYI) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 15 at 1:32 PM
Zacks: Analysts Expect Puma Biotechnology Inc (PBYI) to Announce -$2.02 Earnings Per ShareZacks: Analysts Expect Puma Biotechnology Inc (PBYI) to Announce -$2.02 Earnings Per Share
www.americanbankingnews.com - January 14 at 3:30 AM
Puma Biotech (PBYI) to Modify Neratinib MAA Based on Feedback ... - StreetInsider.comPuma Biotech (PBYI) to Modify Neratinib MAA Based on Feedback ... - StreetInsider.com
www.streetinsider.com - January 13 at 4:25 PM

SEC Filings

Puma Biotechnology (NASDAQ:PBYI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Puma Biotechnology (NASDAQ:PBYI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Puma Biotechnology (NASDAQ PBYI) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.